What Volmax-SR Treats: Main Uses and Benefits

Volmax-SR (Diclofenac SR) is commonly used across domains where additional symptomatic support is needed. It may assist in easing symptoms related to inflammatory or irritative states. The sustained-release formulation is relevant in contexts involving heightened systemic burden where prolonged symptomatic management is appropriate.

---

Therapeutic Scope and Symptom Relief

This medication is applied in clinical settings that involve acute or unstable symptom patterns. It is commonly used to help with groups of symptoms that may become intense or disruptive, such as joint pain, swelling, and stiffness. It is considered relevant for managing conditions that present with significant symptomatic burden, including Rheumatoid Arthritis, Osteoarthritis, Ankylosing Spondylitis, acute gout, and Primary Dysmenorrhea.

“It is commonly used to help with groups of symptoms that may become intense or disruptive, such as joint pain, swelling, and stiffness.”

The primary benefit is that this supportive relief helps patients cope more steadily with symptom fluctuations. It assists with maintaining functional stability during periods of heightened symptoms.

Quick Fact: Relief for Joint Stiffness
Volmax-SR is commonly used to help with symptoms related to physical discomfort, such as stiffness, which often interferes with daily comfort in patients with chronic inflammatory joint conditions.

The eligibility for using Volmax-SR (Diclofenac SR) is strictly defined by regulatory warnings and absolute contraindications. Use is primarily established for adults (18 years and older).

---

Populations for Whom Use is Contraindicated

Volmax-SR must not be used in patients with the following official regulatory contraindications:

• A known allergy or hypersensitivity to diclofenac, aspirin, or any other Nonsteroidal Anti-Inflammatory Drug (NSAID).
• A history of aspirin-sensitive asthma (asthma, hives, or allergic-type reactions after taking an NSAID).
• Active or recurrent gastrointestinal bleeding, ulceration, or perforation.
• In the setting of Coronary Artery Bypass Graft (CABG) surgery.
• Severe hepatic (liver) failure or severe renal (kidney) failure.
• The last trimester of pregnancy (starting at 30 weeks gestation) due to fetal risk.
• Established Ischaemic Heart Disease, Peripheral Arterial Disease, Cerebrovascular Disease, or Congestive Heart Failure (NYHA Class II-IV) (as per European labeling).

---

Age and Condition-Based Restrictions

Category	Official Regulatory Classification
Pediatric Use	Safety and efficacy are not established for children and adolescents under 18.
Pregnancy	Avoid use between 20 and 30 weeks gestation; Contraindicated after 30 weeks.
Advanced Organ Disease	Avoid use in patients with advanced renal disease or severe heart failure unless benefits clearly outweigh the risk of worsening the condition.
Geriatric Use	Use with caution; older adults are at higher risk for serious gastrointestinal or renal events.

Interactions with other medicines and products

Official regulatory documents classify interactions with Volmax-SR (Diclofenac Sodium) based on two main mechanisms: pharmacodynamic reinforcement and pharmacokinetic modification.

Formal Contraindications and Prohibitions

Classification	Interacting Substance/Condition	Constraint as Documented
Contraindicated	Other Systemic NSAIDs / Aspirin	Increases risk of serious gastrointestinal events; risk outweighs benefit [Source: FDA, MHRA].
Contraindicated	CABG Surgery Setting	Prohibited for treating perioperative pain in the setting of Coronary Artery Bypass Graft surgery [Source: FDA].

Clinically Significant Interactions

Interactions that require caution due to modification of drug levels or additive effects include:

• Anticoagulants and Antiplatelet Agents (e.g., Warfarin, Rivaroxaban): Co-administration is associated with an increased risk of serious bleeding due to additive anti-hemostatic effects [Source: FDA, NIH].
• Diuretics and Antihypertensives (e.g., ACE Inhibitors, Furosemide): Diclofenac may diminish the natriuretic and antihypertensive effect of these drugs, which is a pharmacodynamic interaction [Source: FDA].
• Lithium and Methotrexate: Diclofenac may increase the plasma concentrations of these drugs by reducing their renal clearance, raising the potential for toxicity [Source: NIH].
• CYP Inhibitors (e.g., Voriconazole): The co-administration of Voriconazole, which inhibits CYP enzymes, is documented to cause a pharmacokinetic interaction resulting in a significant increase in Diclofenac exposure (Cmax and AUC) [Source: FDA].

Interaction-Related Restrictions

• Alcohol: Use is documented as a risk factor that increases the risk for GI bleeding when taken with NSAIDs [Source: FDA, NIH].
• Population Notes: Elderly patients and those with existing renal or cardiac impairment are identified as being at greater risk for complications from interactions involving antihypertensives and diuretics [Source: FDA].

Volmax-SR is a sustained-release formulation of salbutamol, which functions as a selective beta2-adrenergic receptor agonist.

The drug acts primarily on beta2-adrenergic receptors located on the surface of airway smooth muscle cells. The binding of salbutamol to the beta2-receptor initiates a conformational change in the receptor structure, activating the coupled Gs protein. This protein complex subsequently stimulates the membrane-bound enzyme adenylyl cyclase.

The activation of adenylyl cyclase catalyzes the conversion of intracellular adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP), increasing the intracellular concentration of the latter. Elevated cAMP levels activate protein kinase A (PKA). PKA then phosphorylates multiple intracellular target proteins, leading to a reduction in intracellular calcium ion (Ca^2+) concentration in the smooth muscle cell cytoplasm. The decrease in free Ca^2+ concentration inhibits the enzyme myosin light chain kinase, preventing the phosphorylation of the myosin light chain. This molecular cascade ultimately results in the deactivation of the contractile apparatus, inducing smooth muscle relaxation.

The physiological consequence at the system level is a reduction in airway smooth muscle tone, leading to bronchodilation. The sustained-release formulation provides prolonged receptor occupancy, resulting in a consistent, extended physiological effect.

Instruction Map: How to use Volmax-SR

This map outlines the instructions for the use of Volmax-SR (Diclofenac Sodium Extended-Release 100 mg).

Administration Scope

Category	Instruction
Route of Administration	Oral (by mouth).
Dosing Schedule	The standard adult dose for the relief of symptoms related to Osteoarthritis and Rheumatoid Arthritis is 100 mg per day. The total dose generally should not exceed 100 mg per 24 hours.
Timing in Relation to Meals	May be taken with or without food.
Age-Group Administration	Older adults and individuals with hepatic impairment should initiate treatment with the lowest effective dose.
Missed-Dose Rules	If a dose is missed, the recommended procedure is to skip the missed dose and take the next scheduled dose at the regular time; doubling the dose is not advised.
Special Procedural Conditions	The use protocol specifies employing the lowest effective dose for the shortest duration consistent with individual treatment goals.

---

Resulting Procedural Structure

The Volmax-SR Extended-Release Tablet is intended for once-daily oral administration. To preserve the sustained-release mechanism, the tablet must be swallowed whole and should never be crushed, cut, or chewed. This structure defines a precise set of conditions for ingestion to ensure the 100 mg dose is delivered consistently over the 24-hour period.

Volmax-SR: Recent Clinical Evidence

Volmax-SR is a sustained-release formulation containing Diclofenac, an anti-inflammatory compound that has been evaluated in research contexts involving fluctuating or unstable symptoms. Research primarily involves structured clinical evaluations, such as Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses, which contribute to the broader evidence landscape.

---

Evidence for Symptomatic Relief in Inflammatory Joint Conditions

The research base for Rheumatoid Arthritis (RA) and Osteoarthritis (OA) is characterized by a body of placebo-controlled and active comparator trials. These studies primarily enrolled adults to assess outcomes related to physical discomfort and daily functioning.

In studies exploring RA, researchers used indices to measure changes in joint pain intensity, the duration of morning stiffness, and the count of swollen joints. The short-term RCTs reported patterns in these measurements. For Osteoarthritis, research focused on outcomes reflecting daily functioning and activity level, often measured using validated instruments like the WOMAC Index.

Systematic reviews reported patterns that were documented in regulatory review. However, meta-analyses sometimes report heterogeneity in the findings across studies, meaning evidence quality varies across studies due to differences in trial design or patient populations.

---

Research Gaps and Areas of Scientific Uncertainty

Data for certain groups remain insufficient. Appropriate studies have not been performed to establish the effects of this formulation in the pediatric population (children and adolescents). Similarly, evidence for populations with specific comorbid conditions is often extrapolated from broader patient groups, meaning results apply only to the populations studied in the primary trials.

Long-term follow-up durations were limited in most gold-standard efficacy RCTs. The long-term effects are not fully established by high-quality, controlled trials designed specifically for multi-year follow-up. One key limitation is that most controlled research focuses on symptom change as the primary outcome, without directly examining the drug’s potential effect on the long-term progression of diseases like RA or OA.

Key Studies & References National Institute for Health and Care Excellence (NICE) Guideline: Osteoarthritis: care and management

Common questions about Volmax-SR (FAQ)

---

Q: How long does the sustained-release (SR) effect of Volmax-SR last?

The sustained-release formulation is specifically designed for once-daily use. This dosage form is designed to release the medication slowly and continuously over 24 hours. The goal of this release profile is to help maintain stable drug levels for continuous symptom management.

Q: Are there any common over-the-counter cold medicines that interact with Volmax-SR?

Volmax-SR is a Nonsteroidal Anti-Inflammatory Drug (NSAID). Regulatory warnings advise against using it with other systemic NSAIDs, which are often found as ingredients in common over-the-counter cold and flu preparations. Combining these medications increases the risk of serious gastrointestinal events like bleeding.

Q: What is the difference between Volmax-SR and a regular, non-SR version of the drug?

Volmax-SR is a sustained-release (SR) formulation, meaning it uses a special matrix to deliver the drug slowly. This design helps maintain steady, stable levels of the medication in the body throughout the day. In contrast, non-SR forms release the entire dose more quickly, which can result in sharper peaks in concentration.

Q: Are headaches a common side effect when starting Volmax-SR?

Regulatory documents list headache as a common adverse effect associated with this medication. Concerns about persistent or severe side effects, including headaches, should be addressed by a healthcare professional.

Q: Can other medications for lung conditions be taken alongside Volmax-SR?

The official product information lists potential interactions for many drug classes, such as anticoagulants and blood pressure medications. A healthcare provider should be informed of all co-administered medications to assess for potential unintended effects or interactions with drugs for lung conditions.

Q: Is there published research on the long-term safety of Volmax-SR?

Official information indicates that the long-term effects are not fully established by controlled clinical trials specifically designed for multi-year follow-up. Consistent with regulatory guidance for NSAIDs, the clinical protocol often involves using the lowest effective dose for the shortest duration necessary.

Q: What happens if Volmax-SR is taken closer together than recommended?

The official label states that the total dose generally should not exceed 100 mg per 24 hours. Taking doses too closely together can exceed the labeled maximum daily dose, which is associated with an increased risk of side effects, including serious gastrointestinal or cardiovascular events.

Q: Can Volmax-SR cause changes in my heart rate?

While not a common effect, regulatory documents list rare adverse events such as palpitations (pounding, fluttering, or irregular heartbeats) and arrhythmia (irregular heart rhythm). In cases of overdose, cardiac symptoms such as an increased heart rate are possible.

Q: Do many people experience tremors or 'shakiness' on Volmax-SR?

In official reports, tremors or shakiness are generally documented as a very rare side effect of Diclofenac. Persistent or concerning tremors should be brought to the attention of a healthcare provider.

Q: Is it normal to feel a bit jittery after taking Volmax-SR?

The feeling of being 'jittery' is not a formal adverse event. However, regulatory documents do list rare nervous system effects such as nervousness and anxiety.

Q: Is there a generic version of Volmax-SR available?

Yes, the active ingredient in Volmax-SR is Diclofenac Sodium. This active compound is widely available in various generic sustained-release formulations.

Q: Does Volmax-SR cause insomnia or affect sleep patterns?

Official labeling documents indicate that sleep disturbance, specifically insomnia, is documented as a rare adverse effect associated with this medication.

Q: Does Volmax-SR contain any steroids?

No. Volmax-SR is a Nonsteroidal Anti-Inflammatory Drug (NSAID). It contains the active ingredient Diclofenac Sodium and does not contain any steroid compounds.

Q: Can people with diabetes use Volmax-SR?

Regulatory warnings state that patients with risk factors for cardiovascular disease, such as diabetes mellitus, should be treated with careful consideration. Clinical protocols often involve the use of the lowest effective dose for the shortest duration when this drug is used in such populations.

Q: Is there any risk of physical dependence on Volmax-SR?

Official regulatory labeling contains no warnings or statements that indicate a risk of physical dependence for Diclofenac.

Q: Does Volmax-SR affect blood sugar levels?

The product label advises that patients with existing conditions like diabetes should use this medication with caution. While blood sugar changes are not listed as a common side effect, caution is noted for those with blood sugar conditions.

Q: Is it possible to be allergic to Volmax-SR?

Yes. Volmax-SR is contraindicated (must not be used) in patients who have a known allergy or hypersensitivity to diclofenac, aspirin, or any other Nonsteroidal Anti-Inflammatory Drug (NSAID).

Q: What are the signs of an overdose of Volmax-SR?

Symptoms of a Diclofenac overdose can include lethargy, drowsiness, nausea, vomiting, epigastric pain, and gastrointestinal bleeding. In rare cases, more serious effects like acute kidney failure or coma may occur.

Q: Why is it important for Volmax-SR to be taken at the same time each day?

The extended-release formulation is engineered to maintain a consistent, effective concentration of the drug in your body for 24 hours. Taking it at the same time each day helps ensure that this stable therapeutic level is continuously maintained.

Q: Does Volmax-SR cause weight gain or loss?

Changes in weight (weight gain or weight loss) are documented in the official labeling as an adverse reaction that occurs rarely.

Q: Can Volmax-SR make you feel drowsy or affect driving?

The official labeling notes that side effects such as dizziness or somnolence (drowsiness) may occur. Official labeling contains a warning that individuals experiencing dizziness or drowsiness should avoid driving or operating machinery.

Q: How does the sustained-release mechanism of Volmax-SR benefit patients?

The sustained-release design ensures the medication is delivered slowly and continuously, avoiding the rapid peaks and troughs of drug concentration seen with immediate-release forms. The goal of this release profile is to help maintain stable, effective therapeutic levels for continuous symptom management throughout the day.

Q: What should I do if I accidentally chew or crush a Volmax-SR tablet?

The extended-release tablet must not be crushed or chewed because this action destroys the sustained-release mechanism. This can cause the entire dose to be released at once, increasing the risk of side effects. Medical guidance should be sought if this occurs, as the entire dose may be released suddenly.

How to Store and Dispose of Volmax-SR

Proper storage is essential to maintain the stability of Volmax-SR (Diclofenac SR) tablets, which are required to be stored according to specific regulatory conditions.

---

Official Storage Conditions

Condition	Requirement
Temperature	Store at controlled room temperature (e.g., 15 C to 30 C) and do not store above 25 C; keep from freezing.
Protection	Protect from light and high humidity.
Packaging	Keep in the original, tightly closed container.
Child Safety	Keep out of the reach of children.

---

Official Disposal Rules

Dispose of outdated or unused Volmax-SR following official procedures, such as utilizing a medicine take-back program. The product must not be emptied into drains or released into the environment, as mandated by regulatory guidelines.